EPO and hyperphosphatemia: Experimental data showed that treatment with EPO and HIF-PH inhibitors in anemic mice with CKD reduced iFGF23 levels by more than 70% without causing hyperphosphatemia, improved iron utilization, and restored the balance of genes responsible for 1,25 vitamin D production [77].